Cover Image
市場調查報告書

中國的臨床研究委外機構 (CRO) 產業報告

China Contract Research Organization (CRO) Industry Report, 2017-2021

出版商 ResearchInChina 商品編碼 304490
出版日期 內容資訊 英文 110 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的臨床研究委外機構 (CRO) 產業報告 China Contract Research Organization (CRO) Industry Report, 2017-2021
出版日期: 2017年10月18日 內容資訊: 英文 110 Pages
簡介

本報告提供中國的臨床研究委外機構 (CRO) 產業的相關調查,產業現狀,市場規模,競爭情形,市場特徵,趨勢,國際環境,產業環境,政策環境,今後發展預測的分析,主要企業簡介,為您概述為以下內容。

第1章 醫藥品外包概要

  • 定義
  • 分類
  • CRO (臨床研究委外機構)

第2章 全球CRO產業上演進

  • 發展的過程
  • 發展的背景
  • 市場規模
  • 競爭情形

第3章 中國的CRO產業上的演進

  • 發展環境
  • 現狀
  • 市場規模
  • 競爭格局
  • 發展趨勢

第4章 主要中國企業

  • Wuxi AppTec
  • Hangzhou Tigermed Consulting Co., Ltd.
  • Guangzhou Boji Medical Biotechnological Co., Ltd.
  • Shanghai Medicilon Inc.
  • Porton Fine Chemical Ltd.
  • JOINN Laboratories, Inc.
  • Pharmaron
  • Obio Technology (Shanghai) Corp., Ltd.
  • Asymchem Laboratories Inc.
  • Shanghai ChemPartner Co., Ltd.

第5章 主要國家外企業

  • LabCorp
  • QuintilesIMS
  • Parexel
  • Charles River
  • PPD
  • inVentiv Health

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: ZLC058

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the development of new drugs assisted by CRO firms in recent years, stimulating the progression of global CRO industry which had a market size of USD31.7 billion in 2016.

There are more than 1,100 CRO companies around the world, led by QuintilesIMS, Covance, inVentiv Health, Charles River, Parexel, PPD, ICON and WuXi AppTec. Global top10 CRO firms hold a combined 45% or so market share for now.

image1

China's great competitive edge over the developed countries in pharmaceutical R&D cost has attracted several large international pharmaceutical companies to build dozens of R&D centers here and fueled the development of CRO industry in China. With the scale of about RMB46.2 billion in 2016, the CRO industry in China will maintain a rapid growth rate over the next five years, hitting an estimated RMB116.5 billion in 2021, driven by pharmaceutical companies' more spending on R&D, an increase in the number of new drugs approved and favorable policies.

Leading Chinese CRO companies include WuXi AppTec, Pharmaron, Shanghai Medicilon, Shanghai ChemPartner, Hangzhou Tigermed Consulting, and JOINN Laboratories. WuXi AppTec is one of the most comprehensive service platforms integrating discovery, research and development of small-molecule chemical drugs with the strongest R&D strength and the largest (domestically) and a leading (globally) small-molecule pharmaceutical R&D service business. It occupied about 2% of the world's CRO market and 9.5% of the Chinese CRO market in 2016.

image2

The CRO industry in China will present the following three trends:

  • 1) Pharmaceutical enterprises represented by AvvVie, Novartis, GSK and Eli Lilly and Company have closed or are about to close or sell their R&D centers in China, and will rely more on CRO enterprises for new drug research activities. This will promote the development of CRO industry and be conducive to local CRO enterprises.
  • 2) As the world economy picks up, pharmaceutical enterprises increase their R&D budget gradually, bringing global pharmaceutical R&D spending up to an estimated USD160 billion in 2021, including USD29.2 billion in China. This will drive the development of CRO industry from supply side.
  • 3) Bright prospects of CRO industry and favorable policies in China have attracted enterprises represented by Dian Diagnostics, Xinjiang Baihuacun, Quantum Hi-Tech (China) Biological, and Xiamen Academy Of Building Research Group into the field, to some extent, promoting the development of CRO industry in China.

China Contract Research Organization (CRO) Industry Report, 2017-2021 highlights the followings:

  • Overview of CRO industry (development course/background, market size, competitive landscape, etc.);
  • Overview of CRO industry in China (development environment/status quo, market size, competitive landscape, development trends, etc.);
  • Ten Chinese and six foreign companies (operation, revenue structure, gross margin, R&D investment, etc.)

Table of Contents

1 Overview of Pharmaceutical Outsourcing

  • 1.1 Definition
  • 1.2 Classification
  • 1.3 CRO

2 Evolution of Global CRO Industry

  • 2.1 Development History
  • 2.2 Development Background
  • 2.3 Market Size
  • 2.4 Competitive Landscape

3 Evolution of Chinese CRO Industry

  • 3.1 Development Environment
    • 3.1.1 Regulatory Environment
    • 3.1.2 Policy Environment
    • 3.1.3 Industrial Environment
  • 3.2 Status Quo
  • 3.3 Market Size
  • 3.4 Competitive Pattern
  • 3.5 Development Trends
    • 3.5.1 Transnational Pharmaceutical Companies Shut Down and Have a Clearance Sale of Their Research Centers in China, which Favors Local Chinese Companies
    • 3.5.2 New Drug Approvals Increase and R&D Expenses Grow, Laying a Foundation for the Development of CRO Industry
    • 3.5.3 The Amounting Pressure from R&D Costs Make Pharmaceutical Enterprises Rely More on CRO Companies for the Research and Development of New Drugs
    • 3.5.4 Favorable Policies and Capital Promote the Development of Local Chinese Companies
    • 3.5.5 Good Prospects Attract the Enterprises' Access into CRO Industry

4 Major Chinese Companies

  • 4.1 Wuxi AppTec
    • 4.1.1 Profile
    • 4.1.2 Operation
    • 4.1.3 Revenue Structure
    • 4.1.4 Gross Margin
    • 4.1.5 R&D Expenditure
    • 4.1.6 Major Customers
    • 4.1.7 CRO Business
    • 4.1.8 Prospects
  • 4.2 Hangzhou Tigermed Consulting Co., Ltd.
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 Gross Margin
    • 4.2.5 R&D Expenditure
    • 4.2.6 Prospects
  • 4.3 Guangzhou Boji Medical Biotechnological Co., Ltd.
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 Gross Margin
    • 4.3.5 R&D Expenditure
    • 4.3.6 Prospects
  • 4.4 Shanghai Medicilon Inc.
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 Gross Margin
    • 4.4.5 R&D Expenditure
    • 4.4.6 Major Customers
    • 4.4.7 Prospects
  • 4.5 Porton Fine Chemical Ltd.
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Revenue Structure
    • 4.5.4 Gross Margin
    • 4.5.5 R&D Expenditure
    • 4.5.6 Prospects
  • 4.6 JOINN Laboratories, Inc.
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 Gross Margin
    • 4.6.5 R&D Expenditure
    • 4.6.6 Major Customers
    • 4.6.7 Prospects
  • 4.7 Pharmaron
    • 4.7.1 Profile
    • 4.7.2 Operation
    • 4.7.3 Revenue Structure
    • 4.7.4 Gross Margin
    • 4.7.5 R&D Expenditure
    • 4.7.6 Major Customers
    • 4.7.7 Prospects
  • 4.8 Obio Technology (Shanghai) Corp., Ltd.
    • 4.8.1 Profile
    • 4.8.2 Operation
    • 4.8.3 Revenue Structure
    • 4.8.4 Gross Margin
    • 4.8.5 R&D Expenditure
    • 4.8.6 Major Customers
    • 4.8.7 Prospects
  • 4.9 Asymchem Laboratories Inc.
    • 4.9.1 Profile
    • 4.9.2 Operation
    • 4.9.3 Revenue Structure
    • 4.9.4 Gross Margin
    • 4.9.5 R&D Expenditure
    • 4.9.6 Major Customers
    • 4.9.7 Prospects
  • 4.10 Shanghai ChemPartner Co., Ltd.
    • 4.10.1 Profile
    • 4.10.2 Primary Business
    • 4.10.3 Revenue Structure
    • 4.10.4 Major Customers
    • 4.10.5 Developments

5 Major Foreign Companies

  • 5.1 LabCorp
    • 5.1.1 Profile
    • 5.1.2 Operation
    • 5.1.3 Revenue Structure
    • 5.1.4 CRO Business
    • 5.1.5 Development in China
  • 5.2 QuintilesIMS
    • 5.2.1 Profile
    • 5.2.2 Operation
    • 5.2.3 Revenue Structure
    • 5.2.4 Development in China
  • 5.3 Parexel
    • 5.3.1 Profile
    • 5.3.2 Operation
    • 5.3.3 Revenue Structure
    • 5.3.4 Development in China
  • 5.4 Charles River
    • 5.4.1 Profile
    • 5.4.2 Operation
    • 5.4.3 Revenue Structure
    • 5.4.4 Development in China
  • 5.5 PPD
    • 5.5.1 Profile
    • 5.5.2 Development in China
  • 5.6 inVentiv Health
    • 5.6.1 Profile
    • 5.6.2 Development in China

Selected Charts

  • Classification of Pharmaceutical Outsourcing
  • R&D Process of New Drugs
  • Corresponding Relationship between New Drug R & D Process, New Drug R & D Discipline and CRO Services
  • Global Pharmaceutical Market Size, 2012-2021E
  • Global Pharmaceutical Market Size (by Type), 2012-2021E
  • Global Pharmaceutical Market Size (by Region), 2012-2021E
  • Global Pharmaceutical R & D Investment, 2012-2021E
  • Scale and YoY Growth of Global CRO Industry, 2011-2016
  • Scale and YoY Growth of Global CRO Industry, 2016-2021E
  • Scale and YoY Growth of Global CMO/CDMO Industry, 2011-2016
  • Scale and YoY Growth of Global CMO/CDMO Industry, 2016-2021E
  • Comparison between Global Major CRO Companies
  • Market Share of Global Major CRO Companies, 2014-2016
  • M&A Cases of Global Major CRO Companies
  • Policies on China's CRO Industry, 2010-2017
  • China's Pharmaceutical Market Size and % of the Global Market, 2012-2021E
  • China's Pharmaceutical Market Size (by Type), 2012-2021E
  • China's Pharmaceutical R & D Investment and Its Global Share, 2012-2021E
  • Development Course of China CRO Industry
  • Pharmaceutical R & D Cost Comparison between China and Developed Countries
  • R & D Centers of Multinational Pharmaceutical Companies in China, 2001-2016
  • Scale and YoY Growth of China's CRO Industry, 2011-2016
  • Scale and YoY Growth of China's CRO Industry, 2016-2021E
  • Scale and YoY Growth of China's CMO/CDMO Industry, 2011-2016
  • Scale and YoY Growth of China's CMO/CDMO Industry, 2016-2021E
  • Layout of Major Global CRO Companies in Asia
  • Comparison between Major CRO Companies in China
  • China's CRO Market Share (by Company), 2016
  • Revenue Comparison between Major CRO Companies in China, 2014-2016
  • Net Income Comparison between Major CRO Companies in China, 2014-2016
  • Listing of Local Chinese CRO Companies
  • Layout of Chinese Companies in CRO, 2015-2017
  • Main Business Classification of Wuxi AppTec
  • Revenue and Net Income of Wuxi AppTec, 2014-2017
  • Operating Revenue of Wuxi AppTec (by Business), 2014-2017
  • Operating Revenue Structure of Wuxi AppTec (by Business), 2014-2017
  • Operating Revenue of Wuxi AppTec (by Region), 2014-2017
  • Operating Revenue Structure of Wuxi AppTec (by Region), 2014-2017
  • Gross Margin of Wuxi AppTec, 2014-2017
  • Operating Revenue and Gross Margin of Wuxi AppTec (by Business), 2014-2017
  • R & D Expenditure of Wuxi AppTec and % of Total Revenue, 2014-2017
  • Investment Projects of Wuxi AppTec by Raising Funds via IPO
  • Wuxi AppTec's Revenue from Top 5 Clients and % of Total Revenue, 2014-2017
  • CRO Revenue of Wuxi AppTec (by Business), 2014-2017
  • CRO Gross Margin of Wuxi AppTec (by Business), 2014-2017
  • Revenue and Net Income of Wuxi AppTec, 2016-2021E
  • Revenue and Net Income of Hangzhou Tigermed Consulting, 2013-2017
  • Revenue of Hangzhou Tigermed Consulting (by Business),
  • Revenue Structure of Hangzhou Tigermed Consulting (by Business), 2014-2017
  • Revenue of Hangzhou Tigermed Consulting (by Region), 2014-2017
  • Revenue Structure of Hangzhou Tigermed Consulting (by Region), 2014-2017
  • Gross Margin of Hangzhou Tigermed Consulting (by Business), 2014-2017
  • R & D Expenditure of Hangzhou Tigermed Consulting and % of Total Revenue, 2013-2017
  • Jietongtairui's Financial Data, 2014-2015
  • Expansion of Hangzhou Tigermed Consulting, 2004-2017
  • Revenue and Net Income of Hangzhou Tigermed Consulting, 2016-2021E
  • Revenue and Net Income of Guangzhou Boji Medical Biotechnological, 2014-2017
  • Revenue of Guangzhou Boji Medical Biotechnological (by Business), 2014-2017
  • Gross Margin of Guangzhou Boji Medical Biotechnological (by Business), 2014-2017
  • R & D Expenditure of Guangzhou Boji Medical Biotechnological and % of Total Revenue, 2014-2017
  • Progress of Investment Projects of Guangzhou Boji Medical Biotechnological by Raising Funds via IPO by H1 2017
  • Revenue and Net Income of Guangzhou Boji Medical Biotechnological, 2016-2021E
  • Revenue and Net Income of Shanghai Medicilon, 2014-2016
  • Revenue of Shanghai Medicilon (by Business), 2014-2016
  • Revenue Structure of Shanghai Medicilon (by Business), 2014-2016
  • Revenue of Shanghai Medicilon (by Region), 2014-2016
  • Gross Margin of Shanghai Medicilon (by Business), 2014-2016
  • R & D Expenditure of Shanghai Medicilon and % of Total Revenue, 2014-2016
  • Investment Projects of Shanghai Medicilon by Raising Funds via IPO, 2017
  • Shanghai Medicilon's Revenue from Top 5 Clients and % of Total Revenue, 2014-2016
  • Revenue and Net Income of Shanghai Medicilon, 2016-2021E
  • Revenue and Net Income of Porton Fine Chemical, 2014-2017
  • Revenue of Porton Fine Chemical (by Business), 2014-2017
  • Revenue Structure of Porton Fine Chemical (by Business), 2014-2017
  • Revenue of Porton Fine Chemical (by Region), 2014-2017
  • Revenue Structure of Porton Fine Chemical (by Region), 2014-2017
  • Gross Margin of Porton Fine Chemical (by Business), 2014-2017
  • R & D Expenditure of Porton Fine Chemical and % of Total Revenue, 2014-2017
  • Revenue and Net Income of Porton Fine Chemical, 2016-2021E
  • Revenue and Net Income of JOINN Laboratories, 2014-2016
  • Revenue of JOINN Laboratories (by Business), 2014-2016
  • Revenue Structure of JOINN Laboratories (by Business), 2014-2016
  • Gross Margin of JOINN Laboratories, 2014-2016
  • R & D Expenditure of JOINN Laboratories and % of Total Revenue, 2014-2016
  • Investment Projects of JOINN Laboratories by Raising Funds via IPO, 2017
  • JOINN Laboratories' Revenue from Top 5 Clients and % of Total Revenue, 2014-2016
  • Revenue and Net Income of JOINN Laboratories, 2016-2021E
  • Pharmaron's Revenue and Net Income, 2014-2016
  • Pharmaron's Revenue (by Business), 2014-2016
  • Pharmaron's Gross Margin (by Business), 2014-2016
  • Composition of Pharmaron's R & D Division
  • Pharmaron's Staff Structure by Division
  • Pharmaron's M&A Cases, 2015-2017
  • Pharmaron's Investment Projects by Raising Funds via IPO, 2017
  • Pharmaron's Revenue from Top 5 Clients and % of Total Revenue, 2014-2016
  • Pharmaron's Revenue and Net Income, 2016-2021E
  • Revenue and Net Income of Obio Technology (Shanghai), 2014-2017
  • Revenue of Obio Technology (Shanghai) (by Business), 2014-2017
  • Revenue Structure of Obio Technology (Shanghai) (by Business), 2014-2017
  • Gross Margin of Obio Technology (Shanghai), 2014-2017
  • R & D Expenditure of Obio Technology (Shanghai) and % of Total Revenue, 2014-2017
  • Obio Technology (Shanghai)'s Revenue from Top 5 Clients and % of Total Revenue, 2014-2016
  • Revenue and Net Income of Obio Technology (Shanghai), 2016-2021E
  • Revenue and Net Income of Asymchem Laboratories, 2013-2017
  • Operating Revenue of Asymchem Laboratories (by Business), 2013-2017
  • Operating Revenue Structure of Asymchem Laboratories (by Business), 2013-2017
  • Revenue of Asymchem Laboratories (by Region), 2015-2017
  • Revenue Structure of Asymchem Laboratories (by Region), 2015-2017
  • Gross Margin of Asymchem Laboratories' Main Business, 2013-2017
  • R & D Expenditure of Asymchem Laboratories and % of Total Revenue, 2014-2017
  • Investment Projects of Asymchem Laboratories by Raising Funds via IPO, 2016
  • Asymchem Laboratories' Revenue from Top 5 Clients and % of Total Revenue, 2014-2016
  • Revenue and Net Income of Asymchem Laboratories, 2016-2021E
  • Equity Structure of Shanghai ChemPartnert's Subsidiaries
  • Main Content of Shanghai ChemPartnert's CRO Business
  • Main Content of Shanghai ChemPartnert's CMO Business
  • Revenue of Shanghai ChemPartner (by Business)
  • Revenue of Shanghai ChemPartner (by Region)
  • Shanghai ChemPartnert's Revenue from Major Customers and % of Total Revenue, 2015-2017
  • LabCorp's Revenue and Net Income, 2013-2017
  • LabCorp's Revenue (by Division), 2013-2017
  • LabCorp's Revenue Structure (by Division), 2013-2017
  • LabCorp's CRO Revenue and % of Total Revenue, 2015-2017
  • Revenue and Net Income of QuintilesIMS, 2014-2017
  • Operating Revenue of QuintilesIMS (by Division), 2014-2017
  • Operating Revenue Structure of QuintilesIMS (by Division), 2014-2017
  • Parexel's Revenue and Net Income, FY2014-2017
  • Parexel's Operating Revenue (by Division), FY2014-2017
  • Parexel's Operating Revenue Structure (by Division), FY2014-2017
  • Parexel's Branches in China by H1 2017
  • Revenue and Net Income of Charles River, 2014-2017
  • Revenue of Charles River (by Division), 2014-2017
  • Revenue Structure of Charles River (by Division), 2014-2017
Back to Top